Waldenstrom’s Macroglobulinemia - Pipeline Insight, 2025
Description
DelveInsight’s, “Waldenstrom’s Macroglobulinemia - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Waldenstrom’s Macroglobulinemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Waldenstrom’s Macroglobulinemia: Overview
Waldenstrom Macroglobulinemia (WM) is a lymphoproliferative disorder characterized by the proliferation of lymphoplasmacytic elements in the bone marrow and the presence of monoclonal immunoglobulin M (IgM) gammopathy. The World Health Organization (WHO) classification defined WM as lymphoplasmacytic lymphoma (LPL) screening IgM proteins, belonging to the category of Non-Hodgkin B Lymphomas (NHL) with indolent course. The disease is rare, representing approximately 2% of all cases of non-Hodgkin Lymphoma, and presents distinctive clinical and laboratory features related to the presence of the monoclonal IgM.
The malignant cells in lymphoplasmacytic lymphoma are believed to originate from cells at a late stage of B-cell differentiation. These cells derive from a B-cell arrest after somatic hypermutation in the germinal center and before terminal differentiation to a plasma cell. The pathological findings in lymphoplasmacytic lymphoma are due to infiltration of the bone marrow with small lymphocytes and IgM monoclonal gammopathy. Visual and neurological symptoms are related to hyperviscosity and sluggishness of blood flow. Bleeding encountered in Waldenstrom macroglobulinemia is due to IgM binding to the clotting factors. Cryoglobulinemia in Waldenstrom macroglobulinemia patients leads to Raynaud phenomena and cold urticaria.
The diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia is usually challenging due to the lack of specific morphologic, immunophenotypic, or chromosomal changes. This lack makes the differentiation of this disease entity from other small B cell lymphomas based on exclusion. As a rule, the diagnosis of lymphoplasmacytic lymphoma should be considered in elderly individuals with unexplained weakness, bleeding, neurological deficits, neuropathies, and visual difficulties.
Treatment of Waldenstrom macroglobulinemia depends on the extent of end-organ involvement and symptoms. Asymptomatic patients are managed by close follow-up every 1 to 2 months including serial IgM measurements and assessment of serum viscosity. Symptomatic patients are managed by chemotherapy, immunotherapy, and/or an autologous bone marrow stem cell transplant. Chemotherapeutic agents that are effective in managing Waldenstrom macroglobulinemia include dexamethasone, fludarabine, bortezomib, and cyclophosphamide. A bone marrow transplant is usually reserved for younger patients with more extensive bone marrow involvement. Treatment algorithms for Waldenstrom macroglobulinemia recommend rituximab and bendamustine as a first-line treatment. Several therapeutic novelties have radically changed WM scenario during the last years. Furthermore, the discoveries of two mutations, myeloid differentiation primary response 88 (MYD88) and C-X-C chemokine receptor type 4 (CXCR4) in WM patients has improved disease characterisation helping to deeper understand the biology of the disease.
""Waldenstrom’s Macroglobulinemia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Waldenstrom’s Macroglobulinemia pipeline landscape is provided which includes the disease overview and Waldenstrom’s Macroglobulinemia treatment guidelines. The assessment part of the report embraces, in depth Waldenstrom’s Macroglobulinemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Waldenstrom’s Macroglobulinemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Waldenstrom’s Macroglobulinemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Waldenstrom’s Macroglobulinemia Emerging Drugs
Further product details are provided in the report……..
Waldenstrom’s Macroglobulinemia: Therapeutic Assessment
This segment of the report provides insights about the different Waldenstrom’s Macroglobulinemia drugs segregated based on following parameters that define the scope of the report, such as:
Waldenstrom’s Macroglobulinemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Waldenstrom’s Macroglobulinemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Waldenstrom’s Macroglobulinemia drugs.
Waldenstrom’s Macroglobulinemia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Waldenstrom’s Macroglobulinemia: Overview
Waldenstrom Macroglobulinemia (WM) is a lymphoproliferative disorder characterized by the proliferation of lymphoplasmacytic elements in the bone marrow and the presence of monoclonal immunoglobulin M (IgM) gammopathy. The World Health Organization (WHO) classification defined WM as lymphoplasmacytic lymphoma (LPL) screening IgM proteins, belonging to the category of Non-Hodgkin B Lymphomas (NHL) with indolent course. The disease is rare, representing approximately 2% of all cases of non-Hodgkin Lymphoma, and presents distinctive clinical and laboratory features related to the presence of the monoclonal IgM.
The malignant cells in lymphoplasmacytic lymphoma are believed to originate from cells at a late stage of B-cell differentiation. These cells derive from a B-cell arrest after somatic hypermutation in the germinal center and before terminal differentiation to a plasma cell. The pathological findings in lymphoplasmacytic lymphoma are due to infiltration of the bone marrow with small lymphocytes and IgM monoclonal gammopathy. Visual and neurological symptoms are related to hyperviscosity and sluggishness of blood flow. Bleeding encountered in Waldenstrom macroglobulinemia is due to IgM binding to the clotting factors. Cryoglobulinemia in Waldenstrom macroglobulinemia patients leads to Raynaud phenomena and cold urticaria.
The diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia is usually challenging due to the lack of specific morphologic, immunophenotypic, or chromosomal changes. This lack makes the differentiation of this disease entity from other small B cell lymphomas based on exclusion. As a rule, the diagnosis of lymphoplasmacytic lymphoma should be considered in elderly individuals with unexplained weakness, bleeding, neurological deficits, neuropathies, and visual difficulties.
Treatment of Waldenstrom macroglobulinemia depends on the extent of end-organ involvement and symptoms. Asymptomatic patients are managed by close follow-up every 1 to 2 months including serial IgM measurements and assessment of serum viscosity. Symptomatic patients are managed by chemotherapy, immunotherapy, and/or an autologous bone marrow stem cell transplant. Chemotherapeutic agents that are effective in managing Waldenstrom macroglobulinemia include dexamethasone, fludarabine, bortezomib, and cyclophosphamide. A bone marrow transplant is usually reserved for younger patients with more extensive bone marrow involvement. Treatment algorithms for Waldenstrom macroglobulinemia recommend rituximab and bendamustine as a first-line treatment. Several therapeutic novelties have radically changed WM scenario during the last years. Furthermore, the discoveries of two mutations, myeloid differentiation primary response 88 (MYD88) and C-X-C chemokine receptor type 4 (CXCR4) in WM patients has improved disease characterisation helping to deeper understand the biology of the disease.
""Waldenstrom’s Macroglobulinemia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Waldenstrom’s Macroglobulinemia pipeline landscape is provided which includes the disease overview and Waldenstrom’s Macroglobulinemia treatment guidelines. The assessment part of the report embraces, in depth Waldenstrom’s Macroglobulinemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Waldenstrom’s Macroglobulinemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom’s Macroglobulinemia R&D. The therapies under development are focused on novel approaches to treat/improve Waldenstrom’s Macroglobulinemia.
This segment of the Waldenstrom’s Macroglobulinemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Waldenstrom’s Macroglobulinemia Emerging Drugs
- Lisaftoclax: Ascentage Pharma
- ABT199: Abbvie
- TT-01488: TransThera Biosciences
Further product details are provided in the report……..
Waldenstrom’s Macroglobulinemia: Therapeutic Assessment
This segment of the report provides insights about the different Waldenstrom’s Macroglobulinemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Waldenstrom’s Macroglobulinemia
- There are approx. 20+ key companies which are developing the therapies for Waldenstrom’s Macroglobulinemia. The companies which have their Waldenstrom’s Macroglobulinemia drug candidates in the most advanced stage, i.e. phase II include, Ascentage Pharma.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Waldenstrom’s Macroglobulinemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Waldenstrom’s Macroglobulinemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Waldenstrom’s Macroglobulinemia drugs.
Waldenstrom’s Macroglobulinemia Report Insights
- Waldenstrom’s Macroglobulinemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Waldenstrom’s Macroglobulinemia drugs?
- How many Waldenstrom’s Macroglobulinemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Waldenstrom’s Macroglobulinemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Waldenstrom’s Macroglobulinemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Waldenstrom’s Macroglobulinemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Amgen
- Abbvie
- Roche
- Bristol-Myers Squibb
- X4 Pharmaceuticals
- TransThera Sciences
- BeiGene
- Janssen
- Ascentage Pharma
- Gilead Sciences
- ADC Therapeutics
- InnoCare Pharma
- Mustang Bio
- Carfilzomib
- ABT199
- Obinutuzumab
- Dasatinib
- Mavorixafor
- TT-01488
- BGB 16673
- Zydelig
- Daratumumab
- APG-2575
- loncastuximab tesirine
- Orelabrutinib
- MB-106
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Waldenstrom’s Macroglobulinemia: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Waldenstrom’s Macroglobulinemia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Lisaftoclax: Ascentage Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- TT-01488: TransThera Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Waldenstrom’s Macroglobulinemia Key Companies
- Waldenstrom’s Macroglobulinemia Key Products
- Waldenstrom’s Macroglobulinemia- Unmet Needs
- Waldenstrom’s Macroglobulinemia- Market Drivers and Barriers
- Waldenstrom’s Macroglobulinemia- Future Perspectives and Conclusion
- Waldenstrom’s Macroglobulinemia Analyst Views
- Waldenstrom’s Macroglobulinemia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
